BioCardia (BCDA) AI Stock Analysis

• Market Cap: $12.26M
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.81
• Revenue Growth: -100.00%
• EPS Growth: 58.50%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 10,612,734
• 10 Day Avg. Volume: 282,453
• 30 Day Avg. Volume: 1,147,607
• PEG Ratio: 0.01
• Price to Book (P/B): 7.15
• Price to Sales (P/S): 103.14
• P/FCF Ratio: -0.74
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.43
• Enterprise Value/Ebitda: -0.23
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-13.79% Downside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is primarily constrained by very weak financial performance (no meaningful revenue, ongoing losses, and sustained cash burn), which elevates funding risk. Technicals also remain bearish with the stock below major moving averages, despite oversold signals. Positive clinical/regulatory updates and stated runway into 2026 provide some support, but do not outweigh the current financial and trend headwinds.

Positive Factors

FDA Breakthrough Designation

FDA Breakthrough designation formally recognizes CardiAmp's potential to address an unmet need, accelerating review and facilitating deeper regulator engagement. This durable regulatory status strengthens partnership prospects, may shorten time to market, and supports payer/regulatory dialogue if Phase III succeeds.

Phase III enrollment progressing

Enrollment and randomization in a 250‑patient Phase III confirmatory trial mark a transition to pivotal evidence generation. Sustained site activation and patient flow materially de‑risk the development program, improving the odds of regulatory approval and eventual commercial adoption if trial endpoints are met.

Advancing Japan regulatory pathway (PMDA)

Progressing to formal PMDA consultation opens a distinct approval route in Japan, providing geographic diversification and potential incremental revenue. Successful PMDA engagement can enable country‑specific labeling and reimbursement, strengthening long‑term commercial optionality and partner interest.

Negative Factors

No meaningful revenue

With TTM revenue at $0 and a multi‑year decline in reported sales, BioCardia has not established a commercial revenue base. Lack of operating income means the business cannot self‑fund development, heightening dependence on external financing and increasing execution and dilution risk over the medium term.

Persistent cash burn

Sustained negative operating and free cash flow of roughly -$7.5M TTM underscores ongoing funding needs. Even with reported runway into 2026, continued burn requires further capital or non‑dilutive grants to complete pivotal programs; funding uncertainty is a structural constraint on operations.

Weakened equity base increases financing risk

A materially eroded equity cushion over several years leaves the company with limited capital resilience. A thinner balance sheet reduces ability to absorb clinical or regulatory setbacks, raises the probability of dilutive financings, and constrains strategic optionality for long‑term program support.

BioCardia Business Overview & Revenue Model

Company Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

How the Company Makes Money

BioCardia generates revenue primarily through the commercialization of its cell therapy products, which involve a combination of direct sales, partnerships with healthcare providers, and collaborations with pharmaceutical companies for clinical trials and product development. The company may also receive funding through grants and investments aimed at advancing its research and development efforts. Key revenue streams include sales of its CardiAMP and CardiALLO systems, as well as potential royalties from licensing agreements and partnerships that allow other entities to utilize its technologies in their own therapeutic developments.

BioCardia Financial Statement Overview

Summary

Early-stage profile with minimal revenue (TTM $0) and persistent losses (TTM EBIT about -$8.6M) plus significant cash burn (TTM operating/FCF about -$7.5M). Balance sheet leverage is relatively low (debt-to-equity ~0.24), but the equity base has been pressured over time, increasing financing risk despite some narrowing of losses versus prior years.

Income Statement

BCDA remains in a heavy loss-making phase with no meaningful revenue base: TTM (Trailing-Twelve-Months) revenue is $0 and annual revenue fell sharply from $1.35M (2022) to $0.48M (2023) to $0.06M (2024). Profitability is weak with consistently large operating losses (TTM EBIT of about -$8.6M) and negative gross profit in most periods, indicating the cost structure is far ahead of current commercialization. A modest positive is that losses have narrowed versus 2022–2023 levels, but the overall earnings profile is still highly challenged.

Balance Sheet

Leverage is currently low-to-moderate, with TTM total debt of ~$0.64M against stockholders’ equity of ~$2.63M (debt-to-equity ~0.24), an improvement from 2024 when debt-to-equity was above 1.0. However, the balance sheet has weakened over the multi-year period as equity declined materially (from ~$19.2M in 2020 to ~$0.84M in 2024, then rebounding to ~$2.63M TTM), and losses drive extremely poor returns on equity (TTM ROE is deeply negative). The company is not highly levered, but ongoing losses and a smaller equity cushion increase financial risk.

Cash Flow

Cash burn remains substantial and persistent: TTM operating cash flow is about -$7.5M and free cash flow is about -$7.5M, reflecting continued funding needs. While burn has improved versus 2022–2023 levels (when operating cash flow was roughly -$10M to -$10.6M), free cash flow growth is negative TTM and cash generation is not yet in sight given minimal revenue. Free cash flow tracks net losses closely, underscoring that losses are translating into real cash outflows rather than being primarily non-cash accounting effects.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	58.00K	477.00K	1.35M	1.01M	145.00K
Gross Profit	-4.42M	-4.33M	-7.25M	-7.48M	375.00K	141.00K
EBITDA	-8.44M	-7.93M	-11.56M	-11.82M	-12.57M	-14.44M
Net Income	-8.54M	-7.95M	-11.57M	-11.91M	-12.62M	-15.00M
Balance Sheet
Total Assets	6.15M	3.72M	2.99M	9.79M	15.72M	23.42M
Cash, Cash Equivalents and Short-Term Investments	5.29M	2.37M	1.10M	7.36M	12.87M	21.41M
Total Debt	638.00K	951.00K	1.31M	1.63M	1.87M	614.00K
Total Liabilities	3.52M	2.89M	4.59M	4.90M	5.34M	4.25M
Stockholders Equity	2.63M	837.00K	-1.60M	4.89M	10.38M	19.18M
Cash Flow
Free Cash Flow	-7.51M	-8.03M	-9.99M	-10.63M	-10.48M	-12.39M
Operating Cash Flow	-7.51M	-8.03M	-9.97M	-10.56M	-10.37M	-12.36M
Investing Cash Flow	-2.00K	-6.00K	-12.00K	-70.00K	-116.00K	-32.00K
Financing Cash Flow	7.87M	9.30M	3.73M	5.12M	1.95M	28.21M

BioCardia Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCDA, the sentiment is Negative. The current price of 1.16 is below the 20-day moving average (MA) of 1.22, below the 50-day MA of 1.28, and below the 200-day MA of 1.70, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 37.41 is Neutral, neither overbought nor oversold. The STOCH value of 21.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCDA.

BioCardia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BOLT	48 Neutral	$8.96M	-0.23	-81.97%	―	-46.88%	34.83%
BCDA	45 Neutral	$12.26M	-0.67	-317.47%	―	-100.00%	58.50%
ETHZ	44 Neutral	$68.82M	-0.06	-371.02%	―	―	―
BRTX	44 Neutral	$2.44M	-0.18	-207.73%	―	1.70%	-111.67%
ATON	42 Neutral	$5.99M	>-0.01	―	―	―	―
LYRA	41 Neutral	$2.48M	-0.06	-404.48%	―	-59.21%	68.97%

BioCardia Corporate Events

BioCardia’s CardiAMP Heart Failure Data Selected for LBCT

On February 3, 2026, BioCardia announced that echocardiography data from its CardiAMP Cell Therapy for the treatment of heart failure were accepted for a Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics Meeting, scheduled for March 2–4, 2026, in Boston, Massachusetts. The data, to be presented on March 2 by CardiAMP HF Trial National Co-Principal Investigator Dr. Amish Raval, highlight investigational autologous cell therapy aimed at curbing pathological ventricular remodeling in chronic ischemic heart failure patients with reduced ejection fraction, underscoring BioCardia’s advancing clinical profile and the growing recognition of its FDA Breakthrough-designated, catheter-based therapy, which is supported by the Maryland Stem Cell Research Fund and reimbursed by the Centers for Medicare and Medicaid Services.

The most recent analyst rating on (BCDA) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Advances CardiAMP Therapy in Japan

On December 16, 2025, BioCardia announced the completion of a third preliminary clinical consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) for its CardiAMP Cell Therapy aimed at treating Heart Failure with Reduced Ejection Fraction (HFrEF). The PMDA has agreed to allow BioCardia to advance to a formal clinical consultation, which could lead to regulatory approval in Japan if the data is deemed sufficient. The CardiAMP Cell Therapy, which uses a patient’s own bone marrow cells, has shown positive outcomes in clinical trials, including improved survival rates and reduced major adverse cardiovascular events. This development could significantly impact BioCardia’s operations and its positioning in the cardiovascular therapeutics market.

The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Appoints Marvin Slosman to Board of Directors

On December 2, 2025, BioCardia, Inc. announced the appointment of Marvin Slosman to its Board of Directors, effective immediately, with his term expiring at the 2028 Annual Meeting of Shareholders. Mr. Slosman, who is also the CEO of InspireMD, brings extensive experience in interventional cardiology and global market expansion. His appointment follows the completion of Dr. Richard Krasno’s term, who has been instrumental in guiding the company through significant milestones. The company’s Annual Meeting on the same day saw the election of Class III directors and approval of key proposals, including amendments to the 2016 Equity Incentive Plan and ratification of PKF San Diego, LLP as the independent accounting firm.

The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Appoints New VP of Quality

On November 24, 2025, BioCardia, Inc. announced the appointment of Farhan Shahab as Vice President of Quality. Shahab brings over 25 years of experience in quality management and regulatory roles from various medical and health companies. His expertise is expected to enhance BioCardia’s efforts in commercializing its investigational products, potentially accelerating their market readiness and strengthening the company’s leadership team.

The most recent analyst rating on (BCDA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.

BioCardia Enrolls First Patient in Phase 3 Trial

On November 10, 2025, BioCardia announced the enrollment of the first patient at Henry Ford Health in its Phase 3 CardiAMP HF II clinical trial for ischemic heart failure with reduced ejection fraction. This trial aims to confirm the safety and efficacy of the CardiAMP autologous cell therapy, which previously showed promising results in reducing mortality and improving quality of life for patients. The trial’s success could address significant clinical needs for the approximately 2 million patients in the U.S. and EU suffering from this condition, potentially impacting patient care and the healthcare system.

The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.